Business / Finance

RSS

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.

18 Jun 2013

U.S. MMJ market to quadruple in size over the next five years, predict analysts

Neutra Corp., a provider of all-natural wellness solutions, welcoms a new law passed in Nevada last week allowing medical marijuana patients to obtain their medicine from dispensaries at last.

17 Jun 2013

Transition, Lilly amend agreement to address future development of TT-401

Transition Therapeutics Inc. announced that Eli Lilly and Company has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401.

17 Jun 2013

Biozoom exercises option to acquire 19.9% of Opsolution

Biozoom exercised its option, under a joint venture agreement, to acquire 19.9% of Opsolution, a research and development company dedicated to advancing spectroscopic technology.

15 Jun 2013

Abbott's board authorizes repurchase of up to $3 billion of common stock

Abbott's board of directors has approved a new share repurchase program and declared a quarterly common dividend.

15 Jun 2013

MAXIMUS signs new contract with Maryland Health Benefit Exchange

MAXIMUS, a leading provider of government services worldwide, announced that it has signed a new contract with the Maryland Health Benefit Exchange to operate the Consolidated Service Center, which includes call center, fulfillment and command center services.

14 Jun 2013

Perfinity, Thermo Fisher Scientific sign co-marketing agreement for automated online biopharmaceutical analysis system

Perfinity Biosciences Inc. has announced the signing of an agreement with Thermo Fisher Scientific Inc., the world leader in serving science, to co-market an automated protein sample preparation and analysis system.

From Thermo Fisher Scientific Inc. 13 Jun 2013

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

DSTHS executes contract to provide high quality service to Thrive Health Plans

DST Health Solutions, LLC, a leading provider of technology solutions and services to greater than 250 health plans, integrated delivery systems, and health care providers representing greater than 20 million members, today announced the execution of a contract to provide administration operations, care management, and business analytics to Thrive Health Plans, Inc., a Washington D.C.-based managed care organization which operates under the name Trusted Health Plan.

13 Jun 2013

Mindray announces definitive agreement to acquire ZONARE Medical Systems

Mindray Medical International Limited, today announced a definitive agreement to acquire ZONARE Medical Systems, Inc., an ultrasound technology leader in the high-end radiology segment for US$105 million.

From Mindray 12 Jun 2013

NeuroVive signs agreement with Isomerase Therapeutics to develop and commercialize cyclophilin-inhibiting molecules

NeuroVive Pharmaceutical AB (publ) (STO:NVP), a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from Biotica.

12 Jun 2013

RTI Biologics intents to acquire privately held Pioneer Surgical Technology

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, announced today its intent to acquire privately held Pioneer Surgical Technology, headquartered in Marquette, Mich.

12 Jun 2013

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis Pharma AG and Novartis AG.

11 Jun 2013

Vertical Pharmaceuticals, Nautilus Neurosciences sign co-promotion agreement for Lorzone

Vertical Pharmaceuticals, Inc. today announced that Vertical and Nautilus Neurosciences have entered into a co-promotion agreement for Lorzone (chlorzoxazone tablets, USP), a safe, effective, and fast-acting muscle relaxant that is not associated with significant sedation or drowsiness.

11 Jun 2013

Century Medical to distribute Reverse Medical's products in Japan

Reverse Medical Corporation today announced entering into a strategic partnership agreement with Century Medical, Inc. for distribution of the Reverse Medical products in Japan.

11 Jun 2013

CTI to market ETView Medical's VivaSight products in US

ETView Medical Ltd. announced today that it has entered into an exclusive distribution agreement with Clinical Technologies, Inc.

10 Jun 2013

Diagnoplex secures 1.3 million Swiss francs from financing round

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of companies Debiopharm Group™, with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

7 Jun 2013

Echo Therapeutics declares reverse split of issued and outstanding common stock

Echo Therapeutics, Inc., a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that a 1-for-10 reverse split of the Company's issued and outstanding common stock will be effective prior to the market opening on Friday, June 7, 2013.

7 Jun 2013

Teleflex announces acquisition of Eon Surgical

Teleflex Incorporated, a leading global provider of medical devices for critical care and surgery, today announced the acquisition of Eon Surgical, Ltd., a late stage development company that has advanced a minimally invasive microlaparoscopy surgical platform technology designed to enhance surgeons' ability to perform scarless surgery while producing better patient outcomes.

6 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013